EYD-001 / EydisBio - LARVOL DELTA

A Dual Inhibitor of TAK1 and MAP4K2, NG25, Suppresses Cytokine-driven Inflammation in Juvenile Idiopathic Arthritis Synovial Fibroblasts (ACR Convergence 2025) - "The efficacy of NG25 was further compared with different TAK1 inhibitors (5Z-7-oxozeaenol (5Z), takinib, or HS-276). Our preliminary findings delineate NG25's potential anti-inflammatory and anti-chemotactic activities in JIASFs. These findings lay a foundation for testing the efficacy of NG25 in animal models of JIA."

Idiopathic Arthritis • Immunology • Inflammation • Rheumatology • CDH11 • CXCL5 • CXCL8 • ICAM1 • IFNG • IL1B • IL6 • LY6G6D • MMP3 • PDPN • PTGS2 • TNFA • VCAM1

Inhibition of TAK1 as a novel analgesic for chemotherapy induced peripheral neuropathy (NeuPSIG 2025) - "Furthermore, in the paclitaxel mouse model of CIPN, orally administered EYD-001 was able to prevent the onset of mechanical allodynia, with effects comparable to those observed with gabapentin. These findings underscore the potential of TAK1 inhibitors as a novel therapeutic approach for CIPN. The development of small molecule TAK1 inhibitors for the treatment of CIPN could provide a new class of drugs with improved efficacy and safety profiles compared to current treatments improving the quality of life for individuals undergoing neurotoxic chemotherapies."

CNS Disorders • Pain • TGFB1 • TLR4

Effect of compounds targeting different mechanisms on LPS-induced neuroinflammation (Neuroscience 2024) - "These included HS-276 (TAK1), GSK2982772 (RIPK1), MCC950 (NLRP3), CA-4948 (IRAK4), Tofacitinib citrate (JAK), Psilocybin (5HT2A), and TAK-242 (TLR4). Our data show that TAK-242 inhibits the LPS-induced increase in cytokine mRNA and protein expression in a similar manner to Dexa. TAK-242 is a TLR4 inhibitor which is a known receptor for LPS so this response further validates this in vivo LPS model as a useful approach for testing the efficacy of novel anti-inflammatory agents against neuroinflammation but may only be useful for agents either targeting TLR-4 or its immediate downstream components."

Alzheimer's Disease • CNS Disorders • Parkinson's Disease • IFNG • IL1B • IL6 • IRAK4 • NLRP3 • RIPK1 • TLR4 • TNFA

EydisBio Receives FDA Orphan Drug Designation for TAK1 Inhibitor for the Treatment of Systemic Sclerosis (PRNewswire) - "EydisBio, Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EYD-001, its highly selective and potent, orally bioavailable TAK1 inhibitor for the treatment of systemic sclerosis."

Orphan drug • Immunology • Systemic Sclerosis